Kodiak Sciences Inc. (KOD)
$
22
-0.91 (-4.14%)
Key metrics
Financial statements
Free cash flow per share
-2.4080
Market cap
1.2 Billion
Price to sales ratio
0
Debt to equity
2.6254
Current ratio
1.7848
Income quality
0.5830
Average inventory
0
ROE
-2.4619
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, focuses on the research and development of therapeutics aimed at addressing retinal diseases. Its lead product candidate, KSI-301, is an anti-vascular endothelial growth factor antibody biopolymer currently undergoing Phase IIb/III clinical studies for the treatment of wet age-related macular degeneration (AMD) and other conditions such as diabetic macular edema and non-proliferative diabetic retinopathy. The EBITDA ratio is 0.00 highlighting the company's operational efficiency. The company recorded an operating income of -$186,849,000.00 reflecting its earnings from core operations, while the operating income ratio is 0.00 indicating the company's operational profitability margin. Additionally, it incurred an interest expense of $0.00 reflecting its debt servicing obligations. The net total of other income and expenses is $10,642,000.00 which reflects non-core financial activities. Alongside KSI-301, Kodiak is advancing other preclinical stage product candidates, including KSI-501, a bispecific conjugate targeting retinal diseases with an inflammatory component, and KSI-601, which is a triplet inhibitor designed to treat dry AMD. Originally known as Oligasis, LLC, the company rebranded to Kodiak Sciences Inc. in September 2015 and was incorporated in 2009, with its headquarters based in Palo Alto, California. The stock is affordable at $9.53 making it an attractive option for budget-conscious investors. With a market capitalization of $1,164,464,356.00 the company is classified as a small-cap player. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Additionally, the stock has a low average trading volume of 853,398.00 indicating lower market activity. Kodiak Sciences Inc. belongs to the Healthcare sector, driving innovation and growth in the biopharmaceutical field as it seeks to develop and commercialize promising treatments for retinal diseases.
Is Kodiak Sciences Inc. (KOD) a good investment?
Investing in Kodiak Sciences Inc. (KOD) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Kodiak Sciences Inc. (KOD)'s stock forecast?
Analysts predict Kodiak Sciences Inc. stock to fluctuate between $1.92 (low) and $31.18 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Kodiak Sciences Inc.'s market capitalization?
As of 2026-02-12, Kodiak Sciences Inc.'s market cap is $1,164,464,356, based on 52,930,198 outstanding shares.
How does Kodiak Sciences Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Kodiak Sciences Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Kodiak Sciences Inc. (KOD) stock?
To buy Kodiak Sciences Inc. (KOD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for KOD. Place an order (Market, Limit, etc.).
What is the best time to invest in Kodiak Sciences Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Kodiak Sciences Inc. stock ever split?
Kodiak Sciences Inc.'s last stock split was 5:1 on 2022-02-23.
How did Kodiak Sciences Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$3.35 | Growth: -32.60%.
Where can I find Kodiak Sciences Inc.'s investor relations reports?
Visit https://kodiak.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Kodiak Sciences Inc.?
You can explore historical data from here
What is the all-time high and low for Kodiak Sciences Inc. stock?
All-time high: $131.97 (2021-11-05) | All-time low: $1.37 (2023-10-27).
What are the key trends affecting Kodiak Sciences Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Kodiak Sciences' shares jump 24% in three months as late-stage retinal programs advance and fresh funding extends its cash runway, fueling investor confidence.
seekingalpha.com
Kodiak Sciences Inc. (KOD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
prnewswire.com
PALO ALTO, Calif. , Dec. 18, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the closing of its previously announced underwritten public offering of 8,000,000 shares of its common stock, which includes 1,043,478 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $23.00 per share.
prnewswire.com
PALO ALTO, Calif. , Dec. 16, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the pricing of an upsized underwritten public offering of 6,956,522 shares of its common stock at a price to the public of $23.00 per share.
zacks.com
KOD posts a wider Q3 loss as rising R&D spend fuels advances across its eye-disease pipeline ahead of key data readouts.
prnewswire.com
PALO ALTO, Calif. , Nov. 12, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that Victor Perlroth, M.D.
youtube.com
Alphabet (GOOGL) spiked into its earnings this week, and @stockstotrade's Tim Bohen believes the Google parent company has much more room to run. He explains his bull case that rides on A.I.
prnewswire.com
Meaningful vision gains are rapidly achieved as early as week 4 and more than half of patients in the top two dose levels improved 3-lines or more on the eye chart (≥15 letter gain) A single dose of KSI-101 resulted in the majority of patients achieving resolution of intra-retinal and sub-retinal fluid and over 90% of patients achieved retinal dryness by Week 8 The Phase 3 PEAK and PINNACLE studies of KSI-101 are actively enrolling, testing the top two dose levels (5 mg and 10 mg) in patients with MESI PALO ALTO, Calif. , Sept. 15, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today new data from the APEX study of KSI-101 presented at the Retina Society 58th Annual Scientific Meeting in Chicago, Illinois.
zacks.com
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
prnewswire.com
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its interim results for the six months ended June 30, 2025.
See all news
